OvaScience,Inc. (NASDAQ:OVAS) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

OvaScience,Inc. (NASDAQ:OVAS) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition

On March 2, 2017, OvaScience, Inc. (the “Company”) announced its financial results for the quarter and the year ended December 31, 2016. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1 Press Release dated March 2, 2017.


About OvaScience, Inc. (NASDAQ:OVAS)

OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman’s ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman’s own EggPC cells without the need for hormone hyperstimulation.

OvaScience, Inc. (NASDAQ:OVAS) Recent Trading Information

OvaScience, Inc. (NASDAQ:OVAS) closed its last trading session down -0.01 at 1.49 with 490,955 shares trading hands.